Long‐term disease control and safety with the <scp>anti‐CCR4</scp> antibody mogamulizumab: Post‐hoc analyses from the <scp>MAVORIC</scp> trial of patients with previously treated cutaneous T‐cell lymphoma-Reference-Cited by-同舟云学术

Long‐term disease control and safety with the anti‐CCR4 antibody mogamulizumab: Post‐hoc analyses from the MAVORIC trial of patients with previously treated cutaneous T‐cell lymphoma

Published:2022-06-28 Issue:8 Volume:35 Page:
ISSN:1396-0296
Container-title:Dermatologic Therapy
language:en
Short-container-title:Dermatologic Therapy

Author:

Bagot Martine¹,Dalle Stéphane²,Sokol Lubomir³,Tsianakas Athansios⁴,Musiek Amy⁵,Ortiz‐Romero Pablo L.⁶,Poligone Brian⁷,Duvic Madeleine⁸,Elmets Craig⁹,Leoni Mollie¹⁰,Dwyer Karen¹⁰,Ito Takahiro¹⁰,Herr Fiona¹¹,Kim Youn H.¹²

Affiliation:

1. Hôpital Saint Louis APHP, Inserm U976, Université Paris Cité Paris France

2. Hospices Civils de Lyon Claude Bernard Lyon 1 University Lyon France

3. Department of Malignant Hematology Moffitt Cancer Center Tampa Florida USA

4. Department of Dermatology Specialist Clinic Bad Bentheim Bad Bentheim Germany

5. Division of Dermatology Washington University St. Louis Missouri USA

6. Department of Dermatology Institute i+12, Hospital 12 de Octubre Medical School, University Complutense Madrid Madrid Spain

7. Rochester Skin Lymphoma Medical Group Fairport New York USA

8. Department of Dermatology MD Anderson Cancer Center Houston Texas USA

9. The Department of Dermatology and the O'Neal Comprehensive Cancer Center University of Alabama Birmingham Alabama USA

10. Medical Sciences Kyowa Kirin, Inc Princeton New Jersey USA

11. Medical Affairs Kyowa Kirin, Inc Bedminster New Jersey USA